|Last Price||Today's Change||52-Week Range||Trading Volume|
|21.79||-0.46 (-2.07%)||13.02 - 22.95||97.0 thousand|
Market data as of 4:04PM 12/10/13. Quotes are delayed by at least 15 min.
Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia
12/09/2013 7:00 AM ET